• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Element Biosciences and Bio-Rad Partner to Deliver Seamless RNA Sequencing Workflow Between Element's AVITI™ System and Bio-Rad's SEQuoia™ Express and SEQuoia™ Complete Stranded RNA Library Prep Kits

    2/8/23 8:00:00 AM ET
    $BIO
    $BIO.B
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $BIO alert in real time by email

    SAN DIEGO and HERCULES, Calif., Feb. 8, 2023 /PRNewswire/ -- Element Biosciences, Inc. — the developer of an innovative DNA sequencing platform disrupting genomics — and Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostic products, today announced a partnership to demonstrate the capabilities of the Bio-Rad SEQuoia RNA Sequencing Library Preparation portfolio on the Element AVITI™ Benchtop Sequencer.

    Element Biosciences (PRNewsfoto/Element Biosciences)

    The Element AVITI Sequencing Platform's novel Avidity Sequencing chemistry can be easily adapted for use with the Bio-Rad SEQuoia Complete Stranded RNA Library Prep Kit and the SEQuoia Express Stranded RNA Library Prep Kit to obtain RNA sequencing accuracy and repeatability among samples and different RNA inputs.

    The SEQuoia Complete Stranded RNA Library Prep Kit offers unbiased transcriptome profiling during RNA sequencing by capturing a broad range of RNA subtypes in a single workflow, whether using low or high input RNA. The SEQuoia Express Stranded RNA Library Prep Kit offers the additional benefit of a highly efficient 3-tube workflow for detection of long RNAs that can be completed in only 3 hours.

    The Element AVITI System, a benchtop sequencer with excellent performance, cost savings, and flexibility, combines a simple workflow with exceptional data quality. For enhanced experiment design freedom, the AVITI System features two flow cells, each operating independently, while maintaining the option to deliver up to 2 billion reads of combined sequencing output.

    Recent collaborative studies show high compatibility and performance for RNA sequencing using SEQuoia library preparation chemistries on the Element AVITI System. Bio-Rad will present the results of this collaboration at the Advances in Genome Biology and Technology (AGBT) General Meeting in Hollywood, Florida, on Thursday, February 9, at 8:00 AM in Presidential Suite 3131 of the Diplomat Resort Hotel.

    "The seamless integration of Element's sequencing technology with Bio-Rad's SEQuoia portfolio helps enable cost-effective, flexible, and high-quality sequencing data for our customers," said Shawn Levy, Chief Scientific Officer and Senior Vice President of Applications, Element Biosciences.

    "We are excited to work with Element to provide RNA library preparation chemistries offering high performance for a range of sample types. The collaboration with Element will ensure that our customers can now access this new sequencing platform in a ready-to-use format," said Steven Blakely, Senior Director for the Gene Expression Business, Bio-Rad.

    Please visit bio-rad.com/NGSAGBT2023 to learn more about the SEQuoia RNA-Seq Library Preparation Kits.

    BIO-RAD and SEQuoia are trademarks of Bio-Rad Laboratories in certain jurisdictions. All trademarks used herein are the property of their respective owners.

    About Bio-Rad

    Bio-Rad Laboratories, Inc. (NYSE:BIO) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With 70 years of focus on quality and customer service, our products advance the scientific discovery process and improve healthcare. Our customers are universities, research institutions, hospitals, biotechnology and pharmaceutical companies, as well as public health and commercial laboratories including food safety and environmental quality testing facilities. Based in Hercules, California, Bio-Rad has a global network of operations with approximately 8,200 employees worldwide and $2.9 billion in revenues in 2021. For more information, please visit bio-rad.com.

    About Element Biosciences, Inc.

    Element Biosciences is a multi-disciplinary life science company currently focused on developing disruptive DNA sequencing technology for research and diagnostic markets. Through innovating every fundamental element of a sequencing system, Element empowers customers with affordable, high-quality data and an improved user experience, which in turn will accelerate scientific discoveries and broaden the use of genomic medicine. To learn more about Element, please visit www.elementbiosciences.com.

    Bio-Rad Forward Looking Statements:

    This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our products and our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include the duration and severity of the COVID-19 pandemic, supply chain risks, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad's public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.

    Element Media Contact:

    Kristi Heim

    Element Biosciences

    [email protected]

    Bio-Rad Media Contacts:

    Bio-Rad Laboratories, Inc.

    Katrina Academia, Inbound Marketing Manager

    +1 510-356-7909

    [email protected]

    Zyme Communications

    Esmé Walters

    +44 (0) 7737 543244

    [email protected] 

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/element-biosciences-and-bio-rad-partner-to-deliver-seamless-rna-sequencing-workflow-between-elements-aviti-system-and-bio-rads-sequoia-express-and-sequoia-complete-stranded-rna-library-prep-kits-301741528.html

    SOURCE Element Biosciences

    Get the next $BIO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BIO
    $BIO.B

    CompanyDatePrice TargetRatingAnalyst
    Bio-Rad Laboratories Inc.
    $BIO
    10/1/2024$350.00 → $400.00Neutral → Buy
    Citigroup
    Bio-Rad Laboratories Inc.
    $BIO
    8/28/2024$340.00Equal Weight
    Wells Fargo
    Bio-Rad Laboratories Inc.
    $BIO
    6/3/2024$315.00Hold
    Jefferies
    Bio-Rad Laboratories Inc.
    $BIO
    4/3/2024$400.00 → $365.00Buy → Neutral
    Citigroup
    Bio-Rad Laboratories Inc.
    $BIO
    12/7/2023$395.00Buy
    UBS
    Bio-Rad Laboratories Inc.
    $BIO
    6/16/2023$550.00Overweight
    Wells Fargo
    Bio-Rad Laboratories Inc.
    $BIO
    12/7/2022$565.00Outperform
    RBC Capital Mkts
    Bio-Rad Laboratories Inc.
    $BIO
    8/25/2022$715.00Outperform
    Credit Suisse
    More analyst ratings

    $BIO
    $BIO.B
    SEC Filings

    View All

    SEC Form 10-K filed by Bio-Rad Laboratories Inc.

    10-K - BIO-RAD LABORATORIES, INC. (0000012208) (Filer)

    2/12/26 9:50:30 PM ET
    $BIO.B

    Bio-Rad Laboratories Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - BIO-RAD LABORATORIES, INC. (0000012208) (Filer)

    2/12/26 4:16:35 PM ET
    $BIO.B

    SEC Form 144 filed by Bio-Rad Laboratories Inc.

    144 - BIO-RAD LABORATORIES, INC. (0000012208) (Subject)

    11/6/25 4:24:39 PM ET
    $BIO.B

    $BIO
    $BIO.B
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Bio-Rad Labs upgraded by Citigroup with a new price target

    Citigroup upgraded Bio-Rad Labs from Neutral to Buy and set a new price target of $400.00 from $350.00 previously

    10/1/24 7:11:23 AM ET
    $BIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Wells Fargo initiated coverage on Bio-Rad Labs with a new price target

    Wells Fargo initiated coverage of Bio-Rad Labs with a rating of Equal Weight and set a new price target of $340.00

    8/28/24 7:34:48 AM ET
    $BIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Jefferies resumed coverage on Bio-Rad Labs with a new price target

    Jefferies resumed coverage of Bio-Rad Labs with a rating of Hold and set a new price target of $315.00

    6/3/24 8:40:37 AM ET
    $BIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BIO
    $BIO.B
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, President, LSG Barry James sold $214,289 worth of Bio-Rad A Common Stock (700 units at $306.18), decreasing direct ownership by 58% to 510 units (SEC Form 4)

    4 - BIO-RAD LABORATORIES, INC. (0000012208) (Issuer)

    11/10/25 4:15:49 PM ET
    $BIO.B

    President & COO Divincenzo Jonathan P. converted options into 1,869 units of Bio-Rad A Common Stock and covered exercise/tax liability with 950 units of Bio-Rad A Common Stock (SEC Form 4)

    4 - BIO-RAD LABORATORIES, INC. (0000012208) (Issuer)

    10/28/25 12:29:44 PM ET
    $BIO.B

    EVP, Global Supply Chain Evran Sedat converted options into 1,044 units of Bio-Rad A Common Stock and covered exercise/tax liability with 335 units of Bio-Rad A Common Stock, increasing direct ownership by 47% to 2,233 units (SEC Form 4)

    4 - BIO-RAD LABORATORIES, INC. (0000012208) (Issuer)

    10/21/25 4:42:00 PM ET
    $BIO.B

    $BIO
    $BIO.B
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results

    Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended December 31, 2025. Norman Schwartz, Bio-Rad's Chief Executive Officer, stated: "2025 was a challenging year with geopolitical uncertainty and continued pressure on academic research funding affecting our end markets. While we delivered modest revenue growth and strong free cash flow, our gross and operating margin performance fell below our expectations. The recent acquisition of digital PCR developer Stilla Technologies has been successfully integrated, and we are pleased with the initial market ado

    2/12/26 4:15:00 PM ET
    $BIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bio-Rad to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 12, 2026

    Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, will report its financial results for the fourth quarter and full year 2025 on Thursday, February 12, 2026, following the close of the market. Management will discuss these results in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) that day. To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 outside the U.S., access code: 9562470. A live webcast of the conference call, as well as a supplemental earnings presentation, will also be available in the "Investor Relations" section of the company's website under "Events & Presentations"

    1/29/26 8:30:00 AM ET
    $BIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bio-Rad's Management to Host Investor Meetings at J.P. Morgan's 44th Annual Healthcare Conference

    Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced that the company's Chief Executive Officer Norman Schwartz, Chief Operating Officer Jon DiVincenzo, and Chief Financial Officer Roop K. Lakkaraju will host one-on-one meetings with analysts and investors during J.P. Morgan's 44th Annual Healthcare Conference in San Francisco, CA, January 12-15, 2026. About Bio-Rad Bio-Rad Laboratories, Inc. (NYSE:BIO) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network

    1/6/26 8:45:00 AM ET
    $BIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BIO
    $BIO.B
    Leadership Updates

    Live Leadership Updates

    View All

    Bio-Rad Appoints Rajat Mehta Executive Vice President, Global Commercial Operations

    Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced the appointment of Rajat Mehta as its new Executive Vice President, Global Commercial Operations, effective August 4, 2025. Mehta will lead Bio-Rad's global commercial strategy and execution, succeeding Mike Crowley, who is retiring after a distinguished 26-year career with the company. Mehta brings extensive leadership and commercial expertise in biopharmaceutical, life science research, and diagnostics markets to Bio-Rad. He joins from Labcorp, where he served as Senior Vice President, overseeing large-scale commercial operations for the company's West Divis

    7/28/25 4:15:00 PM ET
    $BIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Sept. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from

    9/6/24 6:43:00 PM ET
    $AAL
    $ADMA
    $ADNT
    Air Freight/Delivery Services
    Consumer Discretionary
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bio-Rad Appoints Jon DiVincenzo President, Chief Operating Officer

    Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced that Jon DiVincenzo will join the company as President and Chief Operating Officer, effective September 9, 2024, replacing Andy Last, who is retiring. Mr. DiVincenzo joins Bio-Rad from Labcorp Holdings Inc., a global provider of comprehensive laboratory services, where he held various global operational and commercial leadership roles across the company's several business units. Most recently, he served as Executive Vice President and President, Central Laboratories and International. Prior to LabCorp, Mr. DiVincenzo was President of the Environmental Health D

    8/20/24 8:30:00 AM ET
    $BIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BIO
    $BIO.B
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Bio-Rad Laboratories Inc.

    SC 13G - BIO-RAD LABORATORIES, INC. (0000012208) (Subject)

    11/14/24 5:25:27 PM ET
    $BIO.B

    Amendment: SEC Form SC 13G/A filed by Bio-Rad Laboratories Inc.

    SC 13G/A - BIO-RAD LABORATORIES, INC. (0000012208) (Subject)

    11/12/24 1:27:07 PM ET
    $BIO.B

    Amendment: SEC Form SC 13G/A filed by Bio-Rad Laboratories Inc.

    SC 13G/A - BIO-RAD LABORATORIES, INC. (0000012208) (Subject)

    11/4/24 11:22:04 AM ET
    $BIO.B

    $BIO
    $BIO.B
    Financials

    Live finance-specific insights

    View All

    Bio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results

    Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended December 31, 2025. Norman Schwartz, Bio-Rad's Chief Executive Officer, stated: "2025 was a challenging year with geopolitical uncertainty and continued pressure on academic research funding affecting our end markets. While we delivered modest revenue growth and strong free cash flow, our gross and operating margin performance fell below our expectations. The recent acquisition of digital PCR developer Stilla Technologies has been successfully integrated, and we are pleased with the initial market ado

    2/12/26 4:15:00 PM ET
    $BIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bio-Rad to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 12, 2026

    Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, will report its financial results for the fourth quarter and full year 2025 on Thursday, February 12, 2026, following the close of the market. Management will discuss these results in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) that day. To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 outside the U.S., access code: 9562470. A live webcast of the conference call, as well as a supplemental earnings presentation, will also be available in the "Investor Relations" section of the company's website under "Events & Presentations"

    1/29/26 8:30:00 AM ET
    $BIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bio-Rad Reports Third-Quarter 2025 Financial Results

    Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced financial results for the third quarter ended September 30, 2025. "During the third quarter, we continued to navigate a dynamic global environment and evolving conditions across the markets for our life science and clinical diagnostics products," stated Norman Schwartz, Bio-Rad's Chairman and CEO. "Despite ongoing challenges in academic research and biotech funding, and the resulting reduced demand for instruments, our teams delivered solid results in Q3. Our ongoing focus on disciplined cost management contributed to a better-than-expected operating margin."

    10/29/25 4:15:00 PM ET
    $BIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials